¿Es justo excluir a millones de personas de un medicamento que puede salvarles la vida?A propósito de la hepatitis C. Autor: nmurcia, publicado por NoGracias, Noviembre 26, 2014.
Is it fair to exclude millions of people from a medication that can save their lives? About Hepatitis C. Author: nmurcia, published by NoGracias, November 26, 2014.
“Investigadores de la Universidad de Liverpool han estimado que todo un curso de tres meses de Sofosbuvir se puede producir por menos de 140 dólares.”
“Researchers at the University of Liverpool have estimated that an entire course of Sofosbuvir therapy during three months may occur for less than $ 140.”
“Experts question the effectiveness of H.P. Acthar Gel, a drug made from pigs’ pituitary glands. Yet it cost Medicare more than $141 million in 2012, up from $7 million in 2008.”
“Medicare covers drugs that are even more expensive. A new drug called Sovaldi, which cures the liver disease hepatitis C, costs $84,000 for a 12-week course of treatment.Experts estimate that Medicare could spend between $2 billion and $6.5 billion on Sovaldi this year alone.”
The Cost Of A Cure: Medicare’s Role In Treating Hepatitis C.
Health Affairs Blog, by Tricia Neuman, Jack Hoadley, and Juliette Cubanski. June 5th, 2014.
“For a patient with hepatitis C, a potentially deadly disease, the prospect of finding a cure with minimal side effects is a really big deal. Also a big deal is the cost of Sovaldi (sofosbuvir), an oral drug approved by the Food and Drug Administration in December 2013 for the treatment of chronic hepatitis C. Sovaldi has been priced by its manufacturer, Gilead, at $1,000 per pill, or an estimated $84,000 for its entire 12-week regimen. It joins the treatment arsenal with several older drugs generally thought either to be less effective or to have more side effects, and another newly approved drug to be taken in combination with other drugs. More drugs are expected to gain approval within the year.”
The high cost of sofosbuvir and ledipasvir threatens population access to hepatitis C therapies. A detailed analysis of human studies is warranted.
The following data is open and transparent:
Ramirez, Jorge H (2014): Database of human studies evaluating the safety and effectiveness of therapies against hepatitis C virus (HCV): sofosbuvir & ledipasvir. figshare.